The role of intravenous sodium bicarbonate in the treatment of metabolic acidosis is controversial.
1
BICAR-ICU, a multicentre, open label, randomised controlled trial, has reignited this debate
2
by reporting a significant reduction in 28-day mortality with sodium bicarbonate treatment in the pre-specified subgroup of patients with severe acidaemia and acute kidney injury.
2
However, as the study was open label, the results are at risk of bias. Blinding of sodium bicarbonate therapy would be important in any future randomised controlled trial, the feasibility of which must be established first. Therefore, we aimed to test the hypothesis that clinicians would be unable to correctly identify a 250 mL polyolefin bag containing 100 mL of 8.4% sodium bicarbonate and 150 mL of 5% dextrose (D5W) from a 250 mL bag of D5W only.
Fujii T, Udy A, Licari E, et al. Sodium bicarbonate therapy for critically ill patients with metabolic acidosis: a scoping and a systematic review. J Crit Care 2019; 51: 184-91.
Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet 2018; 392: 31-40.
Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet 2018; 392: 31-40.